Dx & Vx Co., Ltd.

A180400

KR7180400004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 20/05/2024 BST			5-day change	1st Jan Change
4,130 ^KRW	-3.95%		-8.02%	-30.12%

2023	Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS	CI
2023	Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers	CI

Cancer Rop Co., Ltd. announced that it has received KRW 999.99252 million in funding

June 28, 2020

On June 29, 2020, Cancer Rop., Ltd. (KOSDAQ:A180400) closed the transaction.

Latest news about Dx & Vx Co., Ltd.

Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS	12-20	CI
Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers	27/06/23	CI
Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors	13/06/23	CI
Dx & Vx Co., Ltd. agreed to acquire Avixgen, Inc. from Renaissance Asset Management, Nouveau International Co., Ltd., Lee Mi-ja, Seo Jin - young, Kim Jae-hyun , Cho Il-hyun,Park So -yeon, Jeong Ja -woon, Kim Young- ju, Yang Young-jin, Kim Hye -min and Um In-kyung for KRW 9.2 billion.	23/05/23	CI
DxVx Appoints Kevin Kwon as New President	16/05/23	CI
DxVx Appoints Yong Gu Lee as CEO	16/05/23	CI
Dx & Vx Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	13/04/23	CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors.	06/04/23	CI
Dx & Vx Co., Ltd. announced that it has received KRW 17 billion in funding	05/10/22	CI
Dx & Vx Co., Ltd. completed the acquisition of Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok.	03/10/22	CI
Dx & Vx Co., Ltd. agreed to acquire Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok for approximately KRW 15 billion.	14/09/22	CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 1.78 billion in funding	06/09/22	CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 20 billion in funding	29/08/21	CI
Cancer Rop Co., Ltd. announced that it has received KRW 999.99252 million in funding	28/06/20	CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 999.99252 million in funding	17/06/20	CI
D S and partners limited company cancelled the acquisition of 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd..	28/04/20	CI
Cancer Rop Holdings Co., Ltd. cancelled the acquisition of 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund.	10/07/19	CI
Ds&Partners signed a contract to acquire 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd. for KRW 7.5 billion.	28/04/19	CI
Resort Savers, Inc. Announces Medical Distribution Partnership with South Korea based CancerROP	16/07/18	CI
GI Innovation, Inc. announced that it has received KRW 4.999995 billion in funding from Cancer Rop Co., Ltd.	12/07/18	CI
Cancer Rop Holdings Co., Ltd. singed a contract to acquire 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund for approximately KRW 9.5 billion.	10/07/18	CI
GI Innovation, Inc. announced that it expects to receive KRW 4.999995 billion in funding from Dx & Vx Co., Ltd.	27/06/18	CI
Cancer Rop Co., Ltd. announced that it has received KRW 10 billion in funding	12/04/18	CI
Oxford Vacmedix UK Limited announced that it has received KRW 13.28575 billion in funding from Cancer Rop Co., Ltd.	05/03/18	CI
Oxford Vacmedix UK Limited announced that it expects to receive KRW 10.618366 billion in funding from Cancer Rop Co., Ltd.	04/03/18	CI

Dx & Vx Co Ltd, formerly Cancer Rop Co Ltd, is a Korea-based company primarily engaged in the molecular diagnosis business. The Molecular Diagnosis Business segment is engaged in the manufacture and sale of deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) chips and other products. manufacture and sale of diagnostic reagents used for molecular diagnosis, and various enzymes and experimental reagents used for biological research.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
DX & VX CO., LTD.	-30.12%	91.56M
EXACT SCIENCES CORPORATION	-27.66%	9.88B
IOVANCE BIOTHERAPEUTICS, INC.	+26.94%	2.89B
BGI GENOMICS CO., LTD.	-15.73%	2.12B
VERACYTE, INC.	-20.83%	1.67B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+67.18%	1.45B
CAREDX, INC	+26.08%	788M
SEEGENE, INC.	-4.15%	741M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-28.78%	514M
CURIOX BIOSYSTEMS CO., LTD	+3.98%	308M